Janet K Snell-Bergeon
Overview
Explore the profile of Janet K Snell-Bergeon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
3278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karakus K, Akturk H, Snell-Bergeon J, Shah V
J Diabetes Sci Technol
. 2025 Feb;
:19322968251318740.
PMID: 39950376
Background: To evaluate the progression of diabetic retinopathy (DR) after the initiation of automated insulin delivery (AID) systems in adults with type 1 diabetes (T1D). Methods: In this longitudinal study...
2.
Brigham T, Klein M, Snell-Bergeon J, Polsky S
Acta Diabetol
. 2025 Feb;
PMID: 39945888
Aims: The effectiveness of Hybrid Closed-Loop (HCL) therapy is rarely studied in type 1 diabetes (T1D) pregnancies. Methods: T1D pregnancies (n = 15) managed off-label during gestation using a commercially...
3.
Buschur E, Reedy J, Berget C, Barnard J, Garcetti R, Nease E, et al.
Endocr Pract
. 2025 Jan;
PMID: 39855305
Objective: Type 1 diabetes in pregnancy is challenging. This study explores how assisted hybrid closed-loop therapy (HCL) versus sensor-augmented pump therapy (SAPT) impacts quality of life in pregnancy. Methods: We...
4.
Shao B, Snell-Bergeon J, de Boer I, Davidson W, Bornfeldt K, Heinecke J
J Lipid Res
. 2025 Jan;
66(2):100741.
PMID: 39761918
Atherosclerotic CVD is a major cause of death in individuals with type 1 diabetes mellitus (T1DM). However, conventional risk factors do not fully account for the increased risk. This study...
5.
Snell-Bergeon J, Kaur G, Renner D, Akturk H, Beatson C, Garg S
Diabetes Technol Ther
. 2025 Jan;
27(1):1-9.
PMID: 39745353
Adults with type 1 diabetes (T1D) are increasingly overweight or obese, in part due to intensive insulin therapy. Newer non-insulin medications targeting both hyperglycemia and weight loss are approved for...
6.
DiStefano M, McQueen R, Gao V, Klein M, Snell-Bergeon J, Polsky S
Diabetes Technol Ther
. 2024 Dec;
PMID: 39699652
Data on the cost implications of continuous glucose monitoring (CGM) use in type 1 diabetes (T1D) pregnancies in the United States are sparse. Drawing on associations identified in real-world evidence...
7.
Driscoll K, Geno Rasmussen C, ODonnell H, Trojanowski P, Alman A, Keshawarz A, et al.
Diabetes Res Clin Pract
. 2024 Dec;
219():111947.
PMID: 39689816
Objective: To examine: 1) differences in prevalence of elevated depressive symptoms between individuals with type 1 diabetes (T1D) and without any type of diabetes overall and by sex; and 2)...
8.
Karakus K, Snell-Bergeon J, Akturk H
Diabetes Technol Ther
. 2024 Nov;
PMID: 39514289
To compare the accuracy of commonly used continuous glucose monitoring (CGM) analysis programs with ambulatory glucose profile (AGP) and Dexcom Clarity (DC) in analyzing CGM metrics in patients with type...
9.
Choi Y, Richard G, Zhang G, Hodgin J, Demeke D, Yang Y, et al.
J Clin Invest
. 2024 Oct;
134(24.
PMID: 39436695
BACKGROUNDIn type 1 diabetes (T1D), impaired insulin sensitivity may contribute to the development of diabetic kidney disease (DKD) through alterations in kidney oxidative metabolism.METHODSYoung adults with T1D (n = 30)...
10.
Klein M, Brigham T, Snell-Bergeon J, Polsky S
J Diabetes Sci Technol
. 2024 Jul;
18(5):1263-1264.
PMID: 39044479
No abstract available.